Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CC transcript
Quarterly results
Appointed director
ACURA PHARMACEUTICALS, INC (ACUR) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/17/2021 8-K Quarterly results
Docs: "Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results Palatine, IL – - Acura Pharmaceuticals, Inc. , an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for the third quarter 2021 compared to revenues of $410 thousand, an operating loss of $565 thousand and a net loss of $678 thousand or $0.02 per diluted share for the same period in 2020. For the nine months ended September 30, 2021, the Company reported revenues of $1.5 million, a..."
08/17/2021 8-K Quarterly results
11/17/2020 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2020 2019 Assets – current $ 1,623 $ 1,178 Property, plant and equipment, net 498 540 Other assets 78 844 Total assets $ 2,199 $ 2,562 Other liabilities - current $ 1,021 $ 1,074 Loan under CARES Act - current 164 - Loan under CARES Act - noncurrent 105 - Accrued interest to related party – noncurrent 566 229 Debt to related party – noncurrent 6,000 6,000 Stockholders' deficit Total liabilities and stockholders' deficit $ 2,199 $ 2,562 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS"
08/17/2020 8-K Quarterly results
06/30/2020 8-K Quarterly results
04/01/2020 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, December 31, 2019 2018 Assets - current $ 1,178 $ 461 Property, plant and equipment, net 540 606 Other assets 844 1,085 Total assets $ 2,562 $ 2,152 Liabilities - current $ 1,074 $ 1,435 Accrued interest to related party – non current 229 110 Debt to related party, net – non current 6,000 4,224 Stockholders' deficit Total liabilities and stockholders' deficit $ 2,562 $ 2,152 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS"
03/17/2020 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2019 2018 Assets - current $ 1,015 $ 461 Property, plant and equipment, net 555 606 Other assets 896 1,085 Total assets $ 2,466 $ 2,152 Liabilities - current $ 1,267 $ 1,435 Accrued interest to related party – non current 116 110 Debt to related party, net – non current 6,000 4,224 Stockholders' deficit Total liabilities and stockholders' deficit $ 2,466 $ 2,152 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS"
02/12/2020 8-K Quarterly results
10/04/2019 8-K Quarterly results
Docs: "CONDENSED CONSOLIDATED BALANCE SHEETS March 31, December 31, 2019 2018 Assets – current $ 316 $ 461 Property, plant and equipment, net 589 606 Other assets 1,034 1,085 Total assets $ 1,939 $ 2,152 Liabilities - current $ 1,463 $ 1,435 Accrued interest to related party - current 190 - Debt to related party, net – current 4,647 - Accrued interest to related party – non current - 110 Debt to related party, net – non current - 4,224 Stockholders' deficit Total liabilities and stockholders' deficit $ 1,939 $ 2,152 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS"
09/17/2019 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, December 31, 2018 2017 Assets - current $ 461 $ 2,566 Property, plant and equipment, net 606 679 Other assets 1,085 1,359 Total assets $ 2,152 $ 4,604 Liabilities - current $ 1,435 $ 1,237 Accrued interest - current portion - 700 Debt – current, net - 2,694 Accrued interest to related party, non-current portion 110 - Debt to related party - non-current portion, net 4,224 - Stockholders' deficit Total liabilities and stockholders' deficit $ 2,152 $ 4,604 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF LOSS"
11/27/2018 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2018 2017 Assets - current $ 455 $ 2,566 Property, plant and equipment, net 623 679 Other assets 1,204 1,359 Total assets $ 2,282 $ 4,604 Liabilities - current $ 2,000 $ 1,237 Accrued interest - current portion 781 700 Debt - current, net 1,016 2,694 Accrued interest to related party - non-current 39 - Debt to related party - non-current, net 2,115 - Stockholders' deficit Total liabilities and stockholders' deficit $ 2,282 $ 4,604 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
08/14/2018 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2018 2017 Assets – current $ 916 $ 2,566 Property, plant and equipment, net 641 679 Other assets 1,256 1,359 Total assets $ 2,813 $ 4,604 Liabilities – current $ 1,730 $ 1,237 Accrued interest – current portion 767 700 Debt – current, net 1,505 2,694 Accrued interest – non-current portion 8 - Debt – non-current portion, net 1,429 - Stockholders’ deficit Total liabilities and stockholders’ deficit $ 2,813 $ 4,604 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
06/29/2018 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, December 31, 2018 2017 Assets - current $ 1,082 $ 2,566 Property, plant and equipment, net 659 679 Other assets 1,307 1,359 Total assets $ 3,048 $ 4,604 Liabilities - current $ 1,500 $ 1,237 Accrued interest - current 745 700 Debt – current, net 2,228 2,694 Stockholders' deficit Total liabilities and stockholders' deficit $ 3,048 $ 4,604 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
11/13/2017 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2017 2016 Assets – current $ 4,787 $ 3,410 Assets – restricted - 2,500 Property, plant and equipment, net 699 867 Other assets 1,783 1,431 Total assets $ 7,269 $ 8,208 Liabilities – current $ 1,382 $ 1,111 Debt – current 2,917 2,376 Debt – non-current portion, net of discounts 702 2,979 Accrued interest – non-current portion 668 559 Stockholders’ equity 1,600 1,183 Total liabilities and stockholders’ equity $ 7,269 $ 8,208 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
08/14/2017 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2017 2016 Assets - restricted $ 2,500 $ 2,500 Assets - current 1,692 3,410 Property, plant and equipment, net 720 867 Other assets 1,328 1,431 Total assets $ 6,240 $ 8,208 Liabilities - current $ 1,638 $ 1,111 Debt - current 2,857 2,376 Debt - non-current portion, net of discounts 1,431 2,979 Accrued interest - non-current portion 634 559 Stockholders' equity 1,183 Total liabilities and stockholders' equity $ 6,240 $ 8,208 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
05/12/2017 8-K Form 8-K - Current report
11/14/2016 8-K Form 8-K - Current report
08/08/2016 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2016 2015 Current assets $ 7,678 $ 14,135 Property, plant and equipment, net 1,009 1,013 Other assets 1,535 1,813 Total assets $ 10,222 $ 16,961 Other current liabilities $ 1,314 $ 924 Debt, current 2,629 2,320 Debt, non-current portion - net of discount of $142 and $193, and debt issuance costs of $70 and $97 4,165 5,430 Accrued interest, non-current portion 477 387 Stockholders' equity 1,637 7,900 Total liabilities and stockholders' equity $ 10,222 $ 16,961 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
05/02/2016 8-K Form 8-K - Current report
11/04/2015 8-K Quarterly results
Docs: "ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2015 2014 Current assets $ 16,034 $ 13,231 Property, plant and equipment, net 1,042 957 Other assets 1,865 1,845 Total assets $ 18,941 $ 16,033 Other current liabilities $ 1,369 $ 881 Current deferred revenue - 353 Current maturities of long-term debt 2,470 1,758 Long-term portion of accrued interest 339 190 Long-term debt, net of discount of $220 and $281, and debt issuance costs of $112 and $162 6,038 7,799 Stockholders' equity 8,725 5,052 Total liabilities and stockholders' equity $ 18,941 $ 16,033 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME"
08/03/2015 8-K Quarterly results
Docs: "Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results Palatine, IL – - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2015. The Company reported a net loss of $2.7 million for the second quarter 2015 or $0.05 per diluted share, compared to net loss of $3.5 million or $0.07 per diluted share for the same period in 2014. Revenues for the quarter were $0.3 million compared to $35 thousand in the second quarter of 2014. Research and development expenses associated with product candidates utilizing the Company’ s LIMITX™, and IMPEDE® Technologies were $0.5 million in the second quarter 2015, compared to $1.3 mi..."
05/04/2015 8-K Quarterly results
Docs: "Acura Pharmaceuticals Announces First Quarter 2015 Financial Results Palatine, IL - - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2015. The Company reported net income of $1.2 million for the first quarter 2015 or $0.03 per diluted share, compared to net loss of $4.1 million or $0.08 per diluted share for the same period in 2014. Revenues for the quarter were $5.4 million compared to only $42 thousand in the first quarter of 2014 reflecting the $5.0 million payment arising from licensing Oxaydo to Egalet Corporation entities. Research and development expenses associated with product candidates utilizing the Company’ s LIMITX&trade..."
11/03/2014 8-K Quarterly results
Docs: "Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results Palatine, IL - - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014. The Company reported a net loss of $2.9 million for the third quarter 2014 or $0.06 per diluted share, compared to net loss of $3.2 million or $0.07 per diluted share for the same period in 2013. Research and development expenses associated with product candidates utilizing the Company’ s AVERSION® and IMPEDE® Technologies were $1.0 million in the third quarter 2014, compared to $1.3 million for the same period in 2013. Selling, marketing, general and administrative expenses were $1.7 ..."
08/04/2014 8-K Quarterly results
Docs: "Acura Pharmaceuticals Announces Second Quarter 2014 Financial Results Palatine, IL - - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2014. The Company reported a net loss of $3.5 million for the second quarter 2014 or $0.07 per diluted share, compared to net loss of $3.1 million or $0.07 per diluted share for the same period in 2013. Research and development expenses associated with product candidates utilizing the Company’ s AVERSION® and IMPEDE® Technologies were $1.3 million in the second quarter 2014, compared to $0.8 million for the same period in 2013. Selling, marketing, general and administrative expenses were $1.9 mil..."
05/05/2014 8-K Quarterly results
Docs: "Acura Pharmaceuticals Announces First Quarter 2014 Financial Results Palatine, IL - - Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2014. The Company reported a net loss of $4.1 million for the first quarter 2014 or $0.08 per diluted share, compared to net loss of $4.2 million or $0.09 per diluted share for the same period in 2013. Research and development expenses associated with product candidates utilizing the Company’ s AVERSION® and IMPEDE® Technologies were $1.4 million in the first quarter 2014, compared to $2.0 million for the same period in 2013. Selling, marketing, general and administrative expenses were $2.3 million in t..."
11/04/2013 8-K Form 8-K - Current report
08/01/2013 8-K Form 8-K - Current report
05/02/2013 8-K Form 8-K - Current report
11/06/2012 8-K Form 8-K - Current report
07/30/2012 8-K Form 8-K - Current report
05/01/2012 8-K Form 8-K - Current report
10/31/2011 8-K Form 8-K - Current report
04/28/2011 8-K Quarterly results
Docs: "Acura Pharmaceuticals Reports First Quarter 2011 Financial Results and Product Development Update"
03/01/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy